Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in ...
Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.
The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss ...
Merck Snags Chinese Obesity Drug in Nearly $2 Billion Deal
Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.
Merck Joins With Chinese Distributor On Weight Loss Pill
( MENAFN - Baystreet) Merck (NYSE:MRK) on Wednesday said it has snagged the rights to an experimental weight loss pill from ...
NBC Chicago6d
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker ... are racing to develop more convenient obesity pills that can compete with ...
Zacks.com on MSN5d
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh ...
Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion
Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.